Medication update.
Slagle
Mark
M
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology / Q000627:therapeutic use; D001559:Benzhydryl Compounds / Q000494:pharmacology / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D003408:Cresols / Q000494:pharmacology / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007099:Imipramine / Q000494:pharmacology / Q000627:therapeutic use; D008333:Mandelic Acids / Q000494:pharmacology / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D010665:Phenylpropanolamine; D012076:Renal Agents / Q000494:pharmacology / Q000627:therapeutic use; D000068737:Tolterodine Tartrate; D014549:Urinary Incontinence / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D000929:Antidepressive Agents, Tricyclic; D001559:Benzhydryl Compounds; D018680:Cholinergic Antagonists; D003408:Cresols; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D012076:Renal Agents; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D003894:Deamino Arginine Vasopressin; C005419:oxybutynin; D007099:Imipramine